Conseguenze cliniche ed economiche dello switch ai biosimilari dell’Infliximab nei pazienti reumatologici in Toscana Open new browser tab
(2018)
Start website main content
(2018)
(2018)
(2018)
(2018)
(2018)
(2018)
(2018)
(2018)
(2018)
(2018)